Epilepsy-Pipeline Review, H1 2015

Epilepsy-Pipeline Review, H1 2015

  • Products Id :- GMDHC6014IDB
  • |
  • Pages: 330
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Epilepsy-Pipeline Review, H1 2015


Global Markets Direct's, 'Epilepsy-Pipeline Review, H1 2015', provides an overview of the Epilepsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Epilepsy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Epilepsy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 10

Global Markets Direct Report Coverage 10

Epilepsy Overview 11

Therapeutics Development 12

Pipeline Products for Epilepsy-Overview 12

Pipeline Products for Epilepsy-Comparative Analysis 13

Epilepsy-Therapeutics under Development by Companies 14

Epilepsy-Therapeutics under Investigation by Universities/Institutes 20

Epilepsy-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Epilepsy-Products under Development by Companies 26

Epilepsy-Products under Investigation by Universities/Institutes 35

Epilepsy-Companies Involved in Therapeutics Development 37

Acorda Therapeutics, Inc. 37

Adamas Pharmaceuticals, Inc. 38

Advicenne Pharma 39

Aeolus Pharmaceuticals, Inc. 40

Aestus Therapeutics, Inc. 41

Alexza Pharmaceuticals, Inc. 42

Allergan, Inc. 43

Anavex Life Sciences Corp. 44

Asklepios BioPharmaceutical, Inc. 45

Astellas Pharma Inc. 46

Bial-Portela & Ca, S.A. 47

BioCrea GmbH 48

Bionomics Limited 49

Biovista Inc. 50

Catalyst Pharmaceutical Partners, Inc. 51

Celentyx Ltd. 52

Chong Kun Dang Pharmaceutical Corp. 53

Concert Pharmaceuticals, Inc. 54

Convergence Pharmaceuticals Ltd. 55

D-Pharm Ltd. 56

Desitin Arzneimittel GmbH 57

Eisai Co., Ltd. 58

Epirus Biopharmaceuticals, Inc. 59

Glialogix, Inc. 60

GW Pharmaceuticals plc 61

H. Lundbeck A/S 62

INSYS Therapeutics, Inc. 63

Iproteos S.L. 64

Knopp Biosciences LLC 65

Ligand Pharmaceuticals, Inc. 66

Lipicard Technologies Limited 67

Lohocla Research Corporation 68

Marathon Pharmaceuticals, LLC 69

MarcoPolo Pharmaceuticals SA 70

Marinus Pharmaceuticals, Inc. 71

MedGenesis Therapeutix Inc. 72

Neurocrine Biosciences, Inc. 73

Novartis AG 74

Pfizer Inc. 75

PharmatrophiX, Inc. 76

RestorGenex Corporation 77

Retrophin Inc. 78

Sage Therapeutics 79

Saniona AB 80

SciFluor Life Sciences, LLC 81

SK Biopharmaceuticals Co., Ltd. 82

UCB S.A. 83

Ultragenyx Pharmaceutical Inc. 84

Upsher-Smith Laboratories, Inc. 85

Vichem Chemie Research Ltd. 86

VistaGen Therapeutics, Inc. 87

Zynerba Pharmaceuticals, Inc. 88

Epilepsy-Therapeutics Assessment 89

Assessment by Monotherapy Products 89

Assessment by Target 90

Assessment by Mechanism of Action 95

Assessment by Route of Administration 100

Assessment by Molecule Type 102

Drug Profiles 104

2-DG-Drug Profile 104

ADD-405008-Drug Profile 106

ADS-8800 Series-Drug Profile 107

ADV-5803-Drug Profile 108

ADV-6208-Drug Profile 109

ADV-6769-Drug Profile 110

ADV-6770-Drug Profile 111

AEOL-1114B-Drug Profile 112

AEOL-11203-Drug Profile 113

AEOL-11207-Drug Profile 114

alprazolam-Drug Profile 116

ANAVEX-2-73-Drug Profile 118

AV-101-Drug Profile 119

AVL-5189-Drug Profile 120

BNP-TLE-Drug Profile 121

brivaracetam-Drug Profile 122

BVA-601-Drug Profile 124

C-10068-Drug Profile 125

cannabidiol-Drug Profile 126

carbamazepine-Drug Profile 127

carisbamate-Drug Profile 129

CCG-63802-Drug Profile 131

Cell Therapy for Parkinson's Disease and Epilepsy-Drug Profile 132

CHEC-9-Drug Profile 133

CKD-903-Drug Profile 135

CNV-1061436-Drug Profile 136

cosyntropin-Drug Profile 137

CPP-115-Drug Profile 138

CX-1010-Drug Profile 140

diazepam-Drug Profile 141

diazepam-Drug Profile 142

diazepam-Drug Profile 143

DP-VPA-Drug Profile 145

Drug for Epilepsy-Drug Profile 147

Drug to Agonize GABA Receptor for Epilepsy-Drug Profile 148

Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders-Drug Profile 149

EMSP-Drug Profile 150

Epidiolex-Drug Profile 151

ESB-Drug Profile 153

ESBB-Drug Profile 154

eslicarbazepine acetate-Drug Profile 155

everolimus-Drug Profile 158

fosphenytoin sodium-Drug Profile 163

FV-082-Drug Profile 164

FV-137-Drug Profile 165

ganaxolone-Drug Profile 166

Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy-Drug Profile 168

GLX-1112-Drug Profile 169

GWP-42003-P-Drug Profile 170

GWP-42006-Drug Profile 171

IPR-003-Drug Profile 172

KM-113-Drug Profile 173

KM-314-Drug Profile 174

lacosamide-Drug Profile 175

lamotrigine-Drug Profile 180

levetiracetam-Drug Profile 181

levetiracetam-Drug Profile 184

liatermin-Drug Profile 185

LT-4121-Drug Profile 188

LT-4122-Drug Profile 189

LT-4123-Drug Profile 190

LT-4124-Drug Profile 191

LT-4125-Drug Profile 192

LT-4126-Drug Profile 193

MB-003-Drug Profile 194

midazolam hydrochloride-Drug Profile 195

MRS-5474-Drug Profile 196

MSP-Drug Profile 197

naluzotan-Drug Profile 198

NB-23R1-Drug Profile 199

NGT-168-Drug Profile 200

P-529-Drug Profile 201

perampanel-Drug Profile 203

PF-04895162-Drug Profile 206

PRTT-200-Drug Profile 207

Remegal-Drug Profile 208

rufinamide-Drug Profile 209

SAGE-217-Drug Profile 211

SAGE-547-Drug Profile 212

SAGE-689-Drug Profile 214

SCT-66-Drug Profile 215

selurampanel-Drug Profile 216

SF-0034-Drug Profile 218

SGE-102-Drug Profile 219

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 220

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 221

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 222

Small Molecule for Central Nervous System-Drug Profile 223

Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain-Drug Profile 225

Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy-Drug Profile 226

Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders-Drug Profile 227

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus-Drug Profile 228

Small Molecules for CNS Disorders-Drug Profile 229

Small Molecules for Epilepsy-Drug Profile 230

Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS-Drug Profile 232

Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus-Drug Profile 233

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 234

Small Molecules to Agonize GABA-A Receptor For Epilepsy-Drug Profile 236

Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism-Drug Profile 237

Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System-Drug Profile 238

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 239

Small Molecules to Inhibit Dynamin for Epilepsy and Oncology-Drug Profile 240

sulthiame-Drug Profile 241

TG-4155-Drug Profile 242

tonabersat-Drug Profile 243

topiramate-Drug Profile 244

UBP-608-Drug Profile 245

UX-007-Drug Profile 246

VAD-1-Drug Profile 247

VAD-2-Drug Profile 248

VB-3323-Drug Profile 249

VID-45110-Drug Profile 250

VLB-01-Drug Profile 251

VU-0456810-Drug Profile 252

YKP-3089-Drug Profile 253

Z-944-Drug Profile 255

ZYN-002-Drug Profile 256

Epilepsy-Recent Pipeline Updates 257

Epilepsy-Dormant Projects 303

Epilepsy-Discontinued Products 309

Epilepsy-Product Development Milestones 311

Featured News & Press Releases 311

Appendix 321

Methodology 321

Coverage 321

Secondary Research 321

Primary Research 321

Expert Panel Validation 321

Contact Us 321

Disclaimer 322

List of Tables

Number of Products under Development for Epilepsy, H1 2015 20

Number of Products under Development for Epilepsy-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Development, H1 2015 32

Comparative Analysis by Unknown Stage Development, H1 2015 33

Products under Development by Companies, H1 2015 34

Products under Development by Companies, H1 2015 (Contd..1) 35

Products under Development by Companies, H1 2015 (Contd..2) 36

Products under Development by Companies, H1 2015 (Contd..3) 37

Products under Development by Companies, H1 2015 (Contd..4) 38

Products under Development by Companies, H1 2015 (Contd..5) 39

Products under Development by Companies, H1 2015 (Contd..6) 40

Products under Development by Companies, H1 2015 (Contd..7) 41

Products under Development by Companies, H1 2015 (Contd..8) 42

Products under Investigation by Universities/Institutes, H1 2015 43

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44

Epilepsy-Pipeline by Acorda Therapeutics, Inc., H1 2015 45

Epilepsy-Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 46

Epilepsy-Pipeline by Advicenne Pharma, H1 2015 47

Epilepsy-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 48

Epilepsy-Pipeline by Aestus Therapeutics, Inc., H1 2015 49

Epilepsy-Pipeline by Alexza Pharmaceuticals, Inc., H1 2015 50

Epilepsy-Pipeline by Allergan, Inc., H1 2015 51

Epilepsy-Pipeline by Anavex Life Sciences Corp., H1 2015 52

Epilepsy-Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 53

Epilepsy-Pipeline by Astellas Pharma Inc., H1 2015 54

Epilepsy-Pipeline by Bial-Portela & Ca, S.A., H1 2015 55

Epilepsy-Pipeline by BioCrea GmbH, H1 2015 56

Epilepsy-Pipeline by Bionomics Limited, H1 2015 57

Epilepsy-Pipeline by Biovista Inc., H1 2015 58

Epilepsy-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 59

Epilepsy-Pipeline by Celentyx Ltd., H1 2015 60

Epilepsy-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 61

Epilepsy-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 62

Epilepsy-Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 63

Epilepsy-Pipeline by D-Pharm Ltd., H1 2015 64

Epilepsy-Pipeline by Desitin Arzneimittel GmbH, H1 2015 65

Epilepsy-Pipeline by Eisai Co., Ltd., H1 2015 66

Epilepsy-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 67

Epilepsy-Pipeline by Glialogix, Inc., H1 2015 68

Epilepsy-Pipeline by GW Pharmaceuticals plc, H1 2015 69

Epilepsy-Pipeline by H. Lundbeck A/S, H1 2015 70

Epilepsy-Pipeline by INSYS Therapeutics, Inc., H1 2015 71

Epilepsy-Pipeline by Iproteos S.L., H1 2015 72

Epilepsy-Pipeline by Knopp Biosciences LLC, H1 2015 73

Epilepsy-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 74

Epilepsy-Pipeline by Lipicard Technologies Limited, H1 2015 75

Epilepsy-Pipeline by Lohocla Research Corporation, H1 2015 76

Epilepsy-Pipeline by Marathon Pharmaceuticals, LLC, H1 2015 77

Epilepsy-Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 78

Epilepsy-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 79

Epilepsy-Pipeline by MedGenesis Therapeutix Inc., H1 2015 80

Epilepsy-Pipeline by Neurocrine Biosciences, Inc., H1 2015 81

Epilepsy-Pipeline by Novartis AG, H1 2015 82

Epilepsy-Pipeline by Pfizer Inc., H1 2015 83

Epilepsy-Pipeline by PharmatrophiX, Inc., H1 2015 84

Epilepsy-Pipeline by RestorGenex Corporation, H1 2015 85

Epilepsy-Pipeline by Retrophin Inc., H1 2015 86

Epilepsy-Pipeline by Sage Therapeutics, H1 2015 87

Epilepsy-Pipeline by Saniona AB, H1 2015 88

Epilepsy-Pipeline by SciFluor Life Sciences, LLC, H1 2015 89

Epilepsy-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 90

Epilepsy-Pipeline by UCB S.A., H1 2015 91

Epilepsy-Pipeline by Ultragenyx Pharmaceutical Inc., H1 2015 92

Epilepsy-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 93

Epilepsy-Pipeline by Vichem Chemie Research Ltd., H1 2015 94

Epilepsy-Pipeline by VistaGen Therapeutics , Inc., H1 2015 95

Epilepsy-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 96

Assessment by Monotherapy Products, H1 2015 97

Number of Products by Stage and Target, H1 2015 99

Number of Products by Stage and Mechanism of Action, H1 2015 104

Number of Products by Stage and Route of Administration, H1 2015 109

Number of Products by Stage and Molecule Type, H1 2015 111

Epilepsy Therapeutics-Recent Pipeline Updates, H1 2015 265

Epilepsy-Dormant Projects, H1 2015 311

Epilepsy-Dormant Projects (Contd..1), H1 2015 312

Epilepsy-Dormant Projects (Contd..2), H1 2015 313

Epilepsy-Dormant Projects (Contd..3), H1 2015 314

Epilepsy-Dormant Projects (Contd..4), H1 2015 315

Epilepsy-Dormant Projects (Contd..5), H1 2015 316

Epilepsy-Discontinued Products, H1 2015 317

Epilepsy-Discontinued Products (Contd..1), H1 2015 318

List of Figures

Number of Products under Development for Epilepsy, H1 2015 20

Number of Products under Development for Epilepsy-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Products, H1 2015 32

Assessment by Monotherapy Products, H1 2015 97

Number of Products by Top 10 Targets, H1 2015 98

Number of Products by Stage and Top 10 Targets, H1 2015 98

Number of Products by Top 10 Mechanism of Actions, H1 2015 103

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 103

Number of Products by Top 10 Routes of Administration, H1 2015 108

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 109

Number of Products by Top 10 Molecule Types, H1 2015 110

Number of Products by Stage and Top 10 Molecule Types, H1 2015 110

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Acorda Therapeutics, Inc.

Adamas Pharmaceuticals, Inc.

Advicenne Pharma

Aeolus Pharmaceuticals, Inc.

Aestus Therapeutics, Inc.

Alexza Pharmaceuticals, Inc.

Allergan, Inc.

Anavex Life Sciences Corp.

Asklepios BioPharmaceutical, Inc.

Astellas Pharma Inc.

Bial - Portela & Ca, S.A.

BioCrea GmbH

Bionomics Limited

Biovista Inc.

Catalyst Pharmaceutical Partners, Inc.

Celentyx Ltd.

Chong Kun Dang Pharmaceutical Corp.

Concert Pharmaceuticals, Inc.

Convergence Pharmaceuticals Ltd.

D-Pharm Ltd.

Desitin Arzneimittel GmbH

Eisai Co., Ltd.

Epirus Biopharmaceuticals, Inc.

Glialogix, Inc.

GW Pharmaceuticals plc

H. Lundbeck A/S

INSYS Therapeutics, Inc.

Iproteos S.L.

Knopp Biosciences LLC

Ligand Pharmaceuticals, Inc.

Lipicard Technologies Limited

Lohocla Research Corporation

Marathon Pharmaceuticals, LLC

MarcoPolo Pharmaceuticals SA

Marinus Pharmaceuticals, Inc.

MedGenesis Therapeutix Inc.

Neurocrine Biosciences, Inc.

Novartis AG

Pfizer Inc.

PharmatrophiX, Inc.

RestorGenex Corporation

Retrophin Inc.

Sage Therapeutics

Saniona AB

SciFluor Life Sciences, LLC

SK Biopharmaceuticals Co., Ltd.


Ultragenyx Pharmaceutical Inc.

Upsher-Smith Laboratories, Inc.

Vichem Chemie Research Ltd.

VistaGen Therapeutics, Inc.

Zynerba Pharmaceuticals, Inc.

Epilepsy Therapeutic Products under Development, Key Players in Epilepsy Therapeutics, Epilepsy Pipeline Overview, Epilepsy Pipeline, Epilepsy Pipeline Assessment

select a license

Single User License
USD 2000 INR 136180
Site License
USD 4000 INR 272360
Corporate User License
USD 6000 INR 408540



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com